{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:44:55Z","timestamp":1784555095706,"version":"3.55.0"},"publisher-location":"Cham","reference-count":175,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030580032","type":"print"},{"value":"9783030580049","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/82_2018_102","type":"book-chapter","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T10:39:07Z","timestamp":1532515147000},"page":"1-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Successful Vaccines"],"prefix":"10.1007","author":[{"given":"Ian J.","family":"Amanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"102_CR1","doi-asserted-by":"publisher","unstructured":"Acosta AM et al (2015) Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics 135:981\u2013989. https:\/\/doi.org\/10.1542\/peds.2014-3358","DOI":"10.1542\/peds.2014-3358"},{"key":"102_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1128\/CVI.00609-15","volume":"23","author":"PL Acosta","year":"2016","unstructured":"Acosta PL, Caballero MT, Polack FP (2016) Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 23:189\u2013195. https:\/\/doi.org\/10.1128\/CVI.00609-15","journal-title":"Clin Vaccine Immunol"},{"key":"102_CR3","doi-asserted-by":"publisher","unstructured":"Adams D et al (2015) Summary of notifiable infectious diseases and conditions\u2014United States, 2013 MMWR Morb Mortal Wkly Rep 62:1\u2013122. https:\/\/doi.org\/10.15585\/mmwr.mm6253a1","DOI":"10.15585\/mmwr.mm6253a1"},{"key":"102_CR4","first-page":"1","volume":"46","author":"Advisory Committee on Immunization Practices","year":"1997","unstructured":"Advisory Committee on Immunization Practices (1997) Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. MMWR Recomm Rep 46:1\u201332","journal-title":"MMWR Recomm Rep"},{"key":"102_CR5","first-page":"1","volume":"49","author":"Advisory Committee on Immunization Practices","year":"2000","unstructured":"Advisory Committee on Immunization Practices (2000) Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49:1\u201322","journal-title":"MMWR Recomm Rep"},{"key":"102_CR6","first-page":"425","volume":"16","author":"HE Alexander","year":"1944","unstructured":"Alexander HE, Heidelberger M, Leidy G (1944) The protective or curative element in type B H. influenzae rabbit serum. Yale J Biol Med 16:425\u2013434","journal-title":"Yale J Biol Med"},{"key":"102_CR7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.292.14.1696","volume":"292","author":"LN Alexander","year":"2004","unstructured":"Alexander LN et al (2004) Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696\u20131701","journal-title":"JAMA"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1126\/science.341.6145.454","volume":"341","author":"A Allen","year":"2013","unstructured":"Allen A (2013) Public health. The pertussis paradox. Science 341:454\u2013455. https:\/\/doi.org\/10.1126\/science.341.6145.454","journal-title":"Science"},{"key":"102_CR9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903\u20131915","journal-title":"N Engl J Med"},{"key":"102_CR10","doi-asserted-by":"crossref","unstructured":"Amanna IJ, Messaoudi I, Slifka MK (2008) Protective immunity following vaccination: how is it defined? Hum Vaccine 4:316\u2013319 (5751 [pii])","DOI":"10.4161\/hv.4.4.5751"},{"key":"102_CR11","doi-asserted-by":"publisher","unstructured":"Amanna IJ, Slifka MK (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236:125\u2013138. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00912.x (IMR912 [pii])","DOI":"10.1111\/j.1600-065X.2010.00912.x"},{"key":"102_CR12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","volume":"149","author":"P Anderson","year":"1984","unstructured":"Anderson P (1984) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149:1034\u20131035","journal-title":"J Infect Dis"},{"key":"102_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI106793","volume":"51","author":"P Anderson","year":"1972","unstructured":"Anderson P, Johnston RB Jr, Smith DH (1972) Human serum activities against Hemophilus influenzae, type b. J Clin Invest 51:31\u201338. https:\/\/doi.org\/10.1172\/JCI106793","journal-title":"J Clin Invest"},{"key":"102_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.018","author":"JL Arredondo-Garcia","year":"2018","unstructured":"Arredondo-Garcia JL et al (2018) Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomised controlled trials in Asia and Latin America. Clin Microbiol Infect. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.018","journal-title":"Clin Microbiol Infect"},{"key":"102_CR15","doi-asserted-by":"publisher","unstructured":"August A et al (2017) A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine 35:3749\u20133759. https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.045","DOI":"10.1016\/j.vaccine.2017.05.045"},{"key":"102_CR16","unstructured":"Bacungan VJ, de Guzman C, Hermonio E (2018) TIMELINE: The Dengvaxia controversy. CNN Philippines. http:\/\/cnnphilippines.com\/news\/2017\/12\/09\/The-Dengvaxia-controversy.html . Accessed 12 Feb 2018"},{"key":"102_CR17","first-page":"317","volume":"73","author":"KH Beck","year":"1947","unstructured":"Beck KH, Janney FR (1947) Alexander\u2019s rabbit serum in the treatment of influenzal meningitis; an evaluation of its use in conjunction with sulfonamide compounds. JAMA 73:317\u2013325","journal-title":"JAMA"},{"key":"102_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJM196009152631101","volume":"263","author":"M Beem","year":"1960","unstructured":"Beem M, Wright FH, Hamre D, Egerer R, Oehme M (1960) Association of the chimpanzee coryza agent with acute respiratory disease in children. N Engl J Med 263:523\u2013530. https:\/\/doi.org\/10.1056\/NEJM196009152631101","journal-title":"N Engl J Med"},{"key":"102_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1474-4422(06)70446-X","volume":"5","author":"SF Berkovic","year":"2006","unstructured":"Berkovic SF et al (2006) De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 5:488\u2013492. https:\/\/doi.org\/10.1016\/S1474-4422(06)70446-X","journal-title":"Lancet Neurol"},{"key":"102_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S et al (2013) The global distribution and burden of dengue. Nature 496:504\u2013507. https:\/\/doi.org\/10.1038\/nature12060","journal-title":"Nature"},{"key":"102_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00365548609032332","volume":"18","author":"B Bjorkholm","year":"1986","unstructured":"Bjorkholm B, Bottiger M, Christenson B, Hagberg L (1986) Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis 18:235\u2013239","journal-title":"Scand J Infect Dis"},{"key":"102_CR22","doi-asserted-by":"publisher","unstructured":"Black S, Friedland LR, Schuind A, Howe B (2006) Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4\u20136\u00a0years. Vaccine 24:6163\u20136171 https:\/\/doi.org\/10.1016\/j.vaccine.2006.04.001","DOI":"10.1016\/j.vaccine.2006.04.001"},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.4049\/jimmunol.0901068","volume":"183","author":"M Bonsignori","year":"2009","unstructured":"Bonsignori M et al (2009) HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 183:2708\u20132717. https:\/\/doi.org\/10.4049\/jimmunol.0901068","journal-title":"J Immunol"},{"key":"102_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1128\/CVI.00384-09","volume":"17","author":"R Borrow","year":"2010","unstructured":"Borrow R et al (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17:154\u2013159. https:\/\/doi.org\/10.1128\/CVI.00384-09","journal-title":"Clin Vaccine Immunol"},{"key":"102_CR25","doi-asserted-by":"publisher","first-page":"e1760","DOI":"10.1371\/journal.pntd.0001760","volume":"6","author":"OJ Brady","year":"2012","unstructured":"Brady OJ et al (2012) Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6:e1760. https:\/\/doi.org\/10.1371\/journal.pntd.0001760","journal-title":"PLoS Negl Trop Dis"},{"key":"102_CR26","first-page":"1","volume":"63","author":"EC Briere","year":"2014","unstructured":"Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N (2014) Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 63:1\u201314","journal-title":"MMWR Recomm Rep"},{"key":"102_CR27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4269\/ajtmh.1988.38.172","volume":"38","author":"DS Burke","year":"1988","unstructured":"Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38:172\u2013180","journal-title":"Am J Trop Med Hyg"},{"key":"102_CR28","doi-asserted-by":"publisher","unstructured":"Burton DR, Mascola JR (2015) Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16:571\u2013576. https:\/\/doi.org\/10.1038\/ni.3158ni.3158 [pii]","DOI":"10.1038\/ni.3158ni.3158"},{"key":"102_CR29","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358\u20131365. https:\/\/doi.org\/10.1016\/S0140-6736(14)61060-6","journal-title":"Lancet"},{"key":"102_CR30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa1703309","volume":"377","author":"CV Cardemil","year":"2017","unstructured":"Cardemil CV et al (2017) Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med 377:947\u2013956. https:\/\/doi.org\/10.1056\/NEJMoa1703309","journal-title":"N Engl J Med"},{"key":"102_CR31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jama.1962.03050110016003","volume":"179","author":"CH Carter","year":"1962","unstructured":"Carter CH et al (1962) Serologic response of children to in-activated measles vaccine. JAMA 179:848\u2013853","journal-title":"JAMA"},{"key":"102_CR32","first-page":"1","volume":"45","author":"Centers for Disease Control and Prevention","year":"1996","unstructured":"Centers for Disease Control and Prevention (1996) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 45:1\u201330","journal-title":"MMWR Recomm Rep"},{"key":"102_CR33","unstructured":"Centers for Disease Control and Prevention (2015a) Cervical cancer statistics. Centers for disease control and prevention. http:\/\/www.cdc.gov\/cancer\/cervical\/statistics\/ . Accessed 18 Apr 2016"},{"key":"102_CR34","first-page":"107","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention (2015b) Diphtheria. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 107\u2013118","edition":"13"},{"key":"102_CR35","first-page":"135","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention (2015c) Hepatitis A. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 135\u2013148","edition":"13"},{"key":"102_CR36","first-page":"175","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention (2015d) Human papillomavirus. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 175\u2013186","edition":"13"},{"key":"102_CR37","first-page":"209","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention (2015e) Measles. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 209\u2013230","edition":"13"},{"key":"102_CR38","first-page":"341","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention (2015f) Tetanus. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 341\u2013352","edition":"13"},{"key":"102_CR39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.1961.03040210001001","volume":"176","author":"RM Chanock","year":"1961","unstructured":"Chanock RM, Kim HW, Vargosko AJ, Deleva A, Johnson KM, Cumming C, Parrott RH (1961) Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 176:647\u2013653","journal-title":"JAMA"},{"key":"102_CR40","doi-asserted-by":"publisher","unstructured":"Cherry JD (1999) Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 28(Suppl 2):S107\u2013S111. https:\/\/doi.org\/10.1086\/515057","DOI":"10.1086\/515057"},{"key":"102_CR41","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0264-410X(98)00226-6","volume":"16","author":"JD Cherry","year":"1998","unstructured":"Cherry JD, Gornbein J, Heininger U, Stehr K (1998) A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901\u20131906","journal-title":"Vaccine"},{"key":"102_CR42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","volume":"89","author":"J Chin","year":"1969","unstructured":"Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH (1969) Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89:449\u2013463","journal-title":"Am J Epidemiol"},{"key":"102_CR43","doi-asserted-by":"publisher","unstructured":"Chlibek R et al (2016) Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34:863\u2013868. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.073s0264-410x(15)01349-3 [pii]","DOI":"10.1016\/j.vaccine.2015.09.073s0264-410x(15)01349-3"},{"key":"102_CR44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1542\/peds.68.5.650","volume":"68","author":"CL Cody","year":"1981","unstructured":"Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR (1981) Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68:650\u2013660","journal-title":"Pediatrics"},{"key":"102_CR45","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","volume":"8","author":"PM Day","year":"2010","unstructured":"Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8:260\u2013270. https:\/\/doi.org\/10.1016\/j.chom.2010.08.003","journal-title":"Cell Host Microbe"},{"key":"102_CR46","doi-asserted-by":"publisher","unstructured":"de Taeye SW, Moore JP, Sanders RW (2016) HIV-1 Envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol 37:221\u2013232. https:\/\/doi.org\/10.1016\/j.it.2016.01.007s1471-4906(16)00008-9 [pii]","DOI":"10.1016\/j.it.2016.01.007s1471-4906(16)00008-9"},{"key":"102_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R (2018) Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 67:103\u2013108. https:\/\/doi.org\/10.15585\/mmwr.mm6703a5","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"102_CR48","doi-asserted-by":"publisher","unstructured":"Einstein MH et al (2014) Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345\u00a0years: follow-up through month 48 in a phase III randomized study. Hum Vaccin Immunother 10:3455\u20133465. https:\/\/doi.org\/10.4161\/hv.36117","DOI":"10.4161\/hv.36117"},{"key":"102_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1128\/CVI.00682-14","volume":"22","author":"J Embree","year":"2015","unstructured":"Embree J, Law B, Voloshen T, Tomovici A (2015) Immunogenicity, safety, and antibody persistence at 3, 5, and 10\u00a0years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1\u00a0month apart. Clin Vaccine Immunol 22:282\u2013290. https:\/\/doi.org\/10.1128\/CVI.00682-14","journal-title":"Clin Vaccine Immunol"},{"key":"102_CR50","doi-asserted-by":"publisher","unstructured":"Epstein JE et al (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334:475\u2013480. https:\/\/doi.org\/10.1126\/science.1211548science.1211548 [pii]","DOI":"10.1126\/science.1211548science.1211548"},{"key":"102_CR51","unstructured":"Faulkner A, Skoff T, Martin S, Cassiday P, Tondella ML, Liang J (2015) Chapter 10: Pertussis. In: Manual for the surveillance of vaccine-preventable diseases. Centers for Disease Control and Prevention, Atlanta, GA"},{"key":"102_CR52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF et al (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532\u2013540","journal-title":"J Pediatr"},{"key":"102_CR53","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.1967.03130250057008","volume":"202","author":"VA Fulginiti","year":"1967","unstructured":"Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075\u20131080","journal-title":"JAMA"},{"key":"102_CR54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","volume":"89","author":"VA Fulginiti","year":"1969","unstructured":"Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G (1969) Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89:435\u2013448","journal-title":"Am J Epidemiol"},{"key":"102_CR55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12879-016-1417-2","volume":"16","author":"L Furuya-Kanamori","year":"2016","unstructured":"Furuya-Kanamori L et al (2016) Co-distribution and co-infection of chikungunya and dengue viruses. BMC Infect Dis 16:84. https:\/\/doi.org\/10.1186\/s12879-016-1417-2","journal-title":"BMC Infect Dis"},{"key":"102_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/archdischild-2016-311171","volume":"102","author":"J Garon","year":"2017","unstructured":"Garon J, Patel M (2017) The polio endgame: rationale behind the change in immunisation. Arch Dis Child 102:362\u2013365. https:\/\/doi.org\/10.1136\/archdischild-2016-311171","journal-title":"Arch Dis Child"},{"key":"102_CR57","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.1945.02860320004002","volume":"128","author":"SS Gellis","year":"1945","unstructured":"Gellis SS, Stokes J Jr, Brother GM, Hall WM, Gilmore HR, Beyer E, Morrissey RA (1945) The use of human immune serum globulin (gamma globulin) in infectious (epidemic) hepatitis in the Mediterranean theater of operations I. Studies on prophylaxis in two epidemics of infectious hepatitis. JAMA 128:1062\u20131063","journal-title":"JAMA"},{"key":"102_CR58","doi-asserted-by":"publisher","unstructured":"Giannini SL et al (2006) Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937\u20135949. https:\/\/doi.org\/10.1016\/j.vaccine.2006.06.005 (S0264-410X(06)00709-2 [pii])","DOI":"10.1016\/j.vaccine.2006.06.005"},{"key":"102_CR59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/infdis\/jiv406","volume":"213","author":"GM Glenn","year":"2016","unstructured":"Glenn GM et al (2016) A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 213:411\u2013422. https:\/\/doi.org\/10.1093\/infdis\/jiv406","journal-title":"J Infect Dis"},{"key":"102_CR60","first-page":"3049","volume":"1","author":"M Goulon","year":"1972","unstructured":"Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF (1972) Antitetanus antibodies. Assay before anatoxinotherapy in 64 tetanus patients. Nouv Presse Med 1:3049\u20133050","journal-title":"Nouv Presse Med"},{"key":"102_CR61","doi-asserted-by":"publisher","unstructured":"Gray GE, Laher F, Lazarus E, Ensoli B, Corey L (2016) Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol 17:104\u2013109. https:\/\/doi.org\/10.1016\/j.coviro.2016.02.010 (S1879-6257(16)30014-1 [pii])","DOI":"10.1016\/j.coviro.2016.02.010"},{"key":"102_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6602a1","volume":"66","author":"LA Grohskopf","year":"2017","unstructured":"Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB (2017) Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices\u2014United States, 2017\u201318 Influenza Season. MMWR Recomm Rep 66:1\u201320. https:\/\/doi.org\/10.15585\/mmwr.rr6602a1","journal-title":"MMWR Recomm Rep"},{"key":"102_CR63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1542\/peds.37.4.649","volume":"37","author":"VF Guinee","year":"1966","unstructured":"Guinee VF et al (1966) Cooperative measles vaccine field trial. I. Clinical efficacy. Pediatrics 37:649\u2013665","journal-title":"Pediatrics"},{"key":"102_CR64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1201-9712(02)90072-X","volume":"6","author":"MG Guzman","year":"2002","unstructured":"Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB (2002) Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 6:118\u2013124","journal-title":"Int J Infect Dis"},{"key":"102_CR65","first-page":"270","volume":"21","author":"MG Guzman","year":"1987","unstructured":"Guzman MG et al (1987) Clinical and serologic study of Cuban children with dengue hemorrhagic fever\/dengue shock syndrome (DHF\/DSS). Bull Pan Am Health Organ 21:270\u2013279","journal-title":"Bull Pan Am Health Organ"},{"key":"102_CR66","doi-asserted-by":"crossref","unstructured":"Guzman MG et al (2000) Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 152:793\u2013799 (discussion 804)","DOI":"10.1093\/aje\/152.9.793"},{"key":"102_CR67","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro SR et al (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa1506223","journal-title":"N Engl J Med"},{"key":"102_CR68","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588\u2013598. https:\/\/doi.org\/10.1056\/NEJMoa0804877","journal-title":"N Engl J Med"},{"key":"102_CR69","first-page":"311","volume":"42","author":"SB Halstead","year":"1970","unstructured":"Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42:311\u2013328","journal-title":"Yale J Biol Med"},{"key":"102_CR70","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.vaccine.2016.02.004","volume":"34","author":"SB Halstead","year":"2016","unstructured":"Halstead SB, Russell PK (2016) Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34:1643\u20131647. https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.004","journal-title":"Vaccine"},{"key":"102_CR71","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciw066","volume":"62","author":"E Hammarlund","year":"2016","unstructured":"Hammarlund E et al (2016) Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis. Clin Infect Dis 62:1111\u20131118. https:\/\/doi.org\/10.1093\/cid\/ciw066","journal-title":"Clin Infect Dis"},{"key":"102_CR72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7883\/yoken.JJID.2008.100","volume":"61","author":"L Hao","year":"2008","unstructured":"Hao L, Toyokawa S, Kobayashi Y (2008) Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis 61:100\u2013103","journal-title":"Jpn J Infect Dis"},{"key":"102_CR73","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57:1\u201330 (quiz CE32-34 doi:rr5705a1 [pii])"},{"key":"102_CR74","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jama.1945.02860380028008","volume":"129","author":"WP Havens Jr","year":"1945","unstructured":"Havens WP Jr, Paul JR (1945) Prevention of infectious hepatitis with gamma globulin. JAMA 129:270\u2013272","journal-title":"JAMA"},{"key":"102_CR75","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00006454-199809001-00005","volume":"17","author":"PT Heath","year":"1998","unstructured":"Heath PT (1998) Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 17:S117\u2013S122","journal-title":"Pediatr Infect Dis J"},{"key":"102_CR76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3201\/eid1901.120458","volume":"19","author":"FX Heinz","year":"2013","unstructured":"Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M (2013) Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis 19:69\u201376. https:\/\/doi.org\/10.3201\/eid1901.120458","journal-title":"Emerg Infect Dis"},{"key":"102_CR77","doi-asserted-by":"publisher","unstructured":"Hoffman SL, Vekemans J, Richie TL, Duffy PE (2015) The march toward malaria vaccines. Vaccine 33(Suppl 4):D13\u2013D23 https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.091s0264-410x(15)01070-1 [pii]","DOI":"10.1016\/j.vaccine.2015.07.091s0264-410x(15)01070-1"},{"key":"102_CR78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM195403112501004","volume":"250","author":"DY Hsia","year":"1954","unstructured":"Hsia DY, Lonsway M Jr, Gellis SS (1954) Gamma globulin in the prevention of infectious hepatitis; studies on the use of small doses in family outbreaks. N Engl J Med 250:417\u2013419. https:\/\/doi.org\/10.1056\/NEJM195403112501004","journal-title":"N Engl J Med"},{"key":"102_CR79","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1994.03510410040030","volume":"271","author":"BL Innis","year":"1994","unstructured":"Innis BL et al (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271:1328\u20131334","journal-title":"JAMA"},{"key":"102_CR80","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.1997.03550180045035","volume":"278","author":"HS Izurieta","year":"1997","unstructured":"Izurieta HS, Strebel PM, Blake PA (1997) Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 278:1495\u20131499","journal-title":"JAMA"},{"key":"102_CR81","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1586\/14760584.2016.1105134","volume":"15","author":"N Jaberolansar","year":"2016","unstructured":"Jaberolansar N, Toth I, Young PR, Skwarczynski M (2016) Recent advances in the development of subunit-based RSV vaccines. Expert Rev Vaccines 15:53\u201368. https:\/\/doi.org\/10.1586\/14760584.2016.1105134","journal-title":"Expert Rev Vaccines"},{"key":"102_CR82","unstructured":"Jenner E (1798) An inquiry into the causes and effects of the variolae vaccinae. Sampson Low, London"},{"key":"102_CR83","unstructured":"Jenner E (1799) Further observations on the variolae vaccinae. Sampson Low, London"},{"key":"102_CR84","volume-title":"A continuation of facts and observations relative to the variolae vaccinae, or cowpox","author":"E Jenner","year":"1800","unstructured":"Jenner E (1800) A continuation of facts and observations relative to the variolae vaccinae, or cowpox. Sampson Low, London"},{"key":"102_CR85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","volume":"89","author":"AZ Kapikian","year":"1969","unstructured":"Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89:405\u2013421","journal-title":"Am J Epidemiol"},{"key":"102_CR86","doi-asserted-by":"publisher","unstructured":"Kaslow DC, Biernaux S (2015) RTS,S: Toward a first landmark on the malaria vaccine technology roadmap. Vaccine 33:7425\u20137432. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.061s0264-410x(15)01337-7 [pii]","DOI":"10.1016\/j.vaccine.2015.09.061s0264-410x(15)01337-7"},{"key":"102_CR87","doi-asserted-by":"publisher","first-page":"88","DOI":"10.15585\/mmwr.mm6504a5","volume":"65","author":"DK Kim","year":"2016","unstructured":"Kim DK, Bridges CB, Harriman KH (2016) Advisory Committee on Immunization Practices AAIWG (2016) Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older\u2014United States. MMWR Morb Mortal Wkly Rep 65:88\u201390. https:\/\/doi.org\/10.15585\/mmwr.mm6504a5","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"102_CR88","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422\u2013434","journal-title":"Am J Epidemiol"},{"key":"102_CR89","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","volume":"66","author":"JH Kim","year":"2015","unstructured":"Kim JH, Excler JL, Michael NL (2015) Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 66:423\u2013437. https:\/\/doi.org\/10.1146\/annurev-med-052912-123749","journal-title":"Annu Rev Med"},{"key":"102_CR90","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","volume":"89","author":"R Kirnbauer","year":"1992","unstructured":"Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180\u201312184","journal-title":"Proc Natl Acad Sci USA"},{"key":"102_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2015-3326","volume":"137","author":"NP Klein","year":"2016","unstructured":"Klein NP, Bartlett J, Fireman B, Baxter R (2016) Waning Tdap effectiveness in adolescents. Pediatrics 137:1\u20139. https:\/\/doi.org\/10.1542\/peds.2015-3326","journal-title":"Pediatrics"},{"key":"102_CR92","doi-asserted-by":"publisher","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","volume":"131","author":"NP Klein","year":"2013","unstructured":"Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R (2013) Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 131:e1716\u2013e1722. https:\/\/doi.org\/10.1542\/peds.2012-3836","journal-title":"Pediatrics"},{"key":"102_CR93","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/infdis\/jiu322","volume":"210","author":"R Koepke","year":"2014","unstructured":"Koepke R et al (2014) Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis 210:942\u2013953. https:\/\/doi.org\/10.1093\/infdis\/jiu322","journal-title":"J Infect Dis"},{"key":"102_CR94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJM199607043350107","volume":"335","author":"RG Kost","year":"1996","unstructured":"Kost RG, Straus SE (1996) Postherpetic neuralgia\u2013pathogenesis, treatment, and prevention. N Engl J Med 335:32\u201342. https:\/\/doi.org\/10.1056\/NEJM199607043350107","journal-title":"N Engl J Med"},{"key":"102_CR95","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200104000-00008","volume":"20","author":"P Kramarz","year":"2001","unstructured":"Kramarz P et al (2001) Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 20:410\u2013416","journal-title":"Pediatr Infect Dis J"},{"key":"102_CR96","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","volume":"16","author":"AR Kreimer","year":"2015","unstructured":"Kreimer AR et al (2015) Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 16:775\u2013786. https:\/\/doi.org\/10.1016\/S1470-2045(15)00047-9","journal-title":"Lancet Oncol"},{"key":"102_CR97","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184","journal-title":"N Engl J Med"},{"key":"102_CR98","doi-asserted-by":"publisher","unstructured":"Lee LA et al (2013) The estimated mortality impact of vaccinations forecast to be administered during 2011\u20132020 in 73 countries supported by the GAVI alliance. Vaccine 31(Suppl 2):B61\u2013B72. https:\/\/doi.org\/10.1016\/j.vaccine.2012.11.035","DOI":"10.1016\/j.vaccine.2012.11.035"},{"key":"102_CR99","doi-asserted-by":"publisher","unstructured":"Levin MJ et al (2003) Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188:1336\u20131344. https:\/\/doi.org\/10.1086\/379048 (JID30798 [pii])","DOI":"10.1086\/379048"},{"key":"102_CR100","doi-asserted-by":"publisher","unstructured":"Lieberman JM et al (2006) The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 25:615\u2013622. https:\/\/doi.org\/10.1097\/01.inf.0000220209.35074.0b00006454-200607000-00010 [pii]","DOI":"10.1097\/01.inf.0000220209.35074.0b00006454-200607000-00010"},{"key":"102_CR101","doi-asserted-by":"publisher","unstructured":"Liko J, Robison SG, Cieslak PR (2013) Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 368:581\u2013582. https:\/\/doi.org\/10.1056\/nejmc1212006","DOI":"10.1056\/nejmc1212006"},{"key":"102_CR102","doi-asserted-by":"publisher","unstructured":"Lopez AS et al (2006) One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 117:e1070\u20131077. https:\/\/doi.org\/10.1542\/peds.2005-2085 (117\/6\/e1070 [pii])","DOI":"10.1542\/peds.2005-2085"},{"key":"102_CR103","unstructured":"Marin M, Guris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices CfDC, Prevention (2007) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1\u201340"},{"key":"102_CR104","doi-asserted-by":"publisher","first-page":"33","DOI":"10.15585\/mmwr.mm6701a7","volume":"67","author":"M Marin","year":"2018","unstructured":"Marin M, Marlow M, Moore KL, Patel M (2018) Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep 67:33\u201338. https:\/\/doi.org\/10.15585\/mmwr.mm6701a7","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"102_CR105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bmj.2.4990.454","volume":"2","author":"Medical Research Council","year":"1956","unstructured":"Medical Research Council (1956) Vaccination against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley. Br Med J 2:454\u2013462","journal-title":"Br Med J"},{"key":"102_CR106","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1212\/WNL.30.6.582","volume":"30","author":"AE Miller","year":"1980","unstructured":"Miller AE (1980) Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 30:582\u2013587","journal-title":"Neurology"},{"key":"102_CR107","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1001\/jama.2012.14939","volume":"308","author":"LK Misegades","year":"2010","unstructured":"Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW (2012) Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 308:2126\u20132132. https:\/\/doi.org\/10.1001\/jama.2012.14939","journal-title":"JAMA"},{"key":"102_CR108","doi-asserted-by":"publisher","unstructured":"Morrison VA et al (2015) Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60:900\u2013909. https:\/\/doi.org\/10.1093\/cid\/ciu918ciu918 [pii]","DOI":"10.1093\/cid\/ciu918ciu918"},{"key":"102_CR109","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.1913.04340220001001","volume":"60","author":"JL Morse","year":"1913","unstructured":"Morse JL (1913) Whooping-cough: a plea for more efficient public regulations relative to the control of this most serious and fatal disease. JAMA 60:1677\u20131680","journal-title":"JAMA"},{"key":"102_CR110","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJM200102223440804","volume":"344","author":"TV Murphy","year":"2001","unstructured":"Murphy TV et al (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344:564\u2013572. https:\/\/doi.org\/10.1056\/NEJM200102223440804","journal-title":"N Engl J Med"},{"key":"102_CR111","doi-asserted-by":"publisher","unstructured":"Murray NE, Quam MB, Wilder-Smith A (2013) Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5:299\u2013309. https:\/\/doi.org\/10.2147\/clep.s34440","DOI":"10.2147\/clep.s34440"},{"key":"102_CR112","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545\u20131555. https:\/\/doi.org\/10.1016\/S0140-6736(10)60206-1","journal-title":"Lancet"},{"key":"102_CR113","unstructured":"Novartis Vaccines and Diagnostics (2015) BEXSERO\u00ae (Meningococcal Group B Vaccine) package insert. Cambridge, MA"},{"key":"102_CR114","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/WNL.45.12_Suppl_8.S41","volume":"45","author":"MN Oxman","year":"1995","unstructured":"Oxman MN (1995) Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45:S41\u2013S46","journal-title":"Neurology"},{"key":"102_CR115","doi-asserted-by":"publisher","unstructured":"Oxman MN et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271\u20132284. https:\/\/doi.org\/10.1056\/nejmoa051016 (352\/22\/2271 [pii])","DOI":"10.1056\/nejmoa051016"},{"key":"102_CR116","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161\u20132170","journal-title":"Lancet"},{"key":"102_CR117","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/01.inf.0000086403.50417.7c","volume":"22","author":"Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, Group IS","year":"2003","unstructured":"Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, Group IS (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22:823\u2013827. https:\/\/doi.org\/10.1097\/01.inf.0000086403.50417.7c","journal-title":"Pediatr Infect Dis J"},{"key":"102_CR118","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJM198406143102404","volume":"310","author":"H Peltola","year":"1984","unstructured":"Peltola H, Kayhty H, Virtanen M, Makela PH (1984) Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 310:1561\u20131566. https:\/\/doi.org\/10.1056\/NEJM198406143102404","journal-title":"N Engl J Med"},{"key":"102_CR119","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2165\/11209650-000000000-00000","volume":"72","author":"GL Plosker","year":"2012","unstructured":"Plosker GL (2012) A\/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel(R)]. Drugs 72:1543\u20131557. https:\/\/doi.org\/10.2165\/11209650-000000000-00000","journal-title":"Drugs"},{"key":"102_CR120","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/cid\/cit934","volume":"58","author":"SA Plotkin","year":"2014","unstructured":"Plotkin SA (2014) The pertussis problem Clin Infect Dis 58:830\u2013833. https:\/\/doi.org\/10.1093\/cid\/cit934","journal-title":"The pertussis problem Clin Infect Dis"},{"key":"102_CR121","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","volume":"62","author":"FP Polack","year":"2007","unstructured":"Polack FP (2007) Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 62:111\u2013115. https:\/\/doi.org\/10.1203\/PDR.0b013e3180686ce0","journal-title":"Pediatr Res"},{"key":"102_CR122","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archpedi.1994.02170050037007","volume":"148","author":"DR Prevots","year":"1994","unstructured":"Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL (1994) Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 148:479\u2013485","journal-title":"Arch Pediatr Adolesc Med"},{"key":"102_CR123","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3181\/00379727-160-40422","volume":"160","author":"PJ Provost","year":"1979","unstructured":"Provost PJ, Hilleman MR (1979) Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 160:213\u2013221","journal-title":"Proc Soc Exp Biol Med"},{"key":"102_CR124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jmv.1890190105","volume":"19","author":"PJ Provost","year":"1986","unstructured":"Provost PJ, Hughes JV, Miller WJ, Giesa PA, Banker FS, Emini EA (1986) An inactivated hepatitis A viral vaccine of cell culture origin. J Med Virol 19:23\u201331","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"102_CR125","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/0264-410X(92)90572-2","volume":"10","author":"RH Purcell","year":"1992","unstructured":"Purcell RH, D\u2019Hondt E, Bradbury R, Emerson SU, Govindarajan S, Binn L (1992) Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 10(Suppl 1):S148\u2013S151","journal-title":"Vaccine"},{"key":"102_CR126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archpedi.1965.02090020234007","volume":"109","author":"LW Rauh","year":"1965","unstructured":"Rauh LW, Schmidt R (1965) Measles immunization with killed virus vaccine. Serum Antibody Titers and Experience with Exposure to Measles Epidemic. Am J Dis Child 109:232\u2013237","journal-title":"Am J Dis Child"},{"key":"102_CR127","doi-asserted-by":"publisher","unstructured":"Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U (2007) Persistence of seroprotection 10\u00a0years after primary hepatitis A vaccination in an unselected study population. Vaccine 25:927\u2013931. https:\/\/doi.org\/10.1016\/j.vaccine.2006.08.044","DOI":"10.1016\/j.vaccine.2006.08.044"},{"key":"102_CR128","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1542\/peds.2010-0887","volume":"128","author":"IS Reyes","year":"2011","unstructured":"Reyes IS, Hsieh DT, Laux LC, Wilfong AA (2011) Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics 128:e699\u2013e702. https:\/\/doi.org\/10.1542\/peds.2010-0887","journal-title":"Pediatrics"},{"key":"102_CR129","doi-asserted-by":"publisher","unstructured":"Richie TL et al (2015) Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33:7452\u20137461. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.096s0264-410x(15)01386-9 [pii]","DOI":"10.1016\/j.vaccine.2015.09.096s0264-410x(15)01386-9"},{"key":"102_CR130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/B978-1-4557-0090-5.00039-2","volume-title":"Vaccines","author":"M Roper","year":"2013","unstructured":"Roper M, Wassilak S, Tiwari T, Orenstein W (2013) Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 6th edn. Saunders\/Elsevier, Philadelphia, pp 746\u2013772","edition":"6"},{"key":"102_CR131","doi-asserted-by":"publisher","unstructured":"RTS-S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31\u201345. https:\/\/doi.org\/10.1016\/s0140-6736(15)60721-8s0140-6736(15)60721-8 [pii]","DOI":"10.1016\/s0140-6736(15)60721-8s0140-6736(15)60721-8"},{"key":"102_CR132","doi-asserted-by":"publisher","unstructured":"Sabchareon A et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559\u20131567. https:\/\/doi.org\/10.1016\/s0140-6736(12)61428-7 (S0140-6736(12)61428-7 [pii])","DOI":"10.1016\/s0140-6736(12)61428-7"},{"key":"102_CR133","doi-asserted-by":"publisher","unstructured":"Safaeian M et al (2013) Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res (Phila) 6:1242\u20131250. https:\/\/doi.org\/10.1158\/1940-6207.capr-13-0203","DOI":"10.1158\/1940-6207.capr-13-0203"},{"key":"102_CR134","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0022-3476(47)80280-X","volume":"30","author":"W Sako","year":"1947","unstructured":"Sako W (1947) Studies on pertussis immunization. J Pediatr 30:29\u201340","journal-title":"J Pediatr"},{"key":"102_CR135","unstructured":"Sanofi Pasteur (2017) Dengue vaccine registered in 19 countries. http:\/\/dengue.info\/dengue-vaccine-registered-in-19-countries\/ . Accessed 12 Feb 2018"},{"key":"102_CR136","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1542\/peds.85.4.662","volume":"85","author":"M Santosham","year":"1990","unstructured":"Santosham M, Reid R, Letson GW, Wolff MC, Siber G (1990) Passive immunization for infection with Haemophilus influenzae type b. Pediatrics 85:662\u2013666","journal-title":"Pediatrics"},{"key":"102_CR137","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1128\/IAI.58.10.3369-3374.1990","volume":"58","author":"H Sato","year":"1990","unstructured":"Sato H, Sato Y (1990) Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun 58:3369\u20133374","journal-title":"Infect Immun"},{"key":"102_CR138","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1386-6532(00)00091-3","volume":"19","author":"JT Schiller","year":"2000","unstructured":"Schiller JT, Hidesheim A (2000) Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 19:67\u201374","journal-title":"J Clin Virol"},{"key":"102_CR139","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1006\/scbi.1996.0046","volume":"7","author":"JT Schiller","year":"1996","unstructured":"Schiller JT, Lowy DR (1996) Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 7:373\u2013382. https:\/\/doi.org\/10.1006\/scbi.1996.0046","journal-title":"Semin Cancer Biol"},{"key":"102_CR140","doi-asserted-by":"publisher","unstructured":"Schmader KE et al (2012) Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 55:1320\u20131328. https:\/\/doi.org\/10.1093\/cid\/cis638cis638 [pii]","DOI":"10.1093\/cid\/cis638cis638"},{"key":"102_CR141","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.107.4.1081","volume":"107","author":"R Schneerson","year":"1971","unstructured":"Schneerson R, Rodrigues LP, Parke JC Jr, Robbins JB (1971) Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of \u201cnatural,\u201d infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b. J Immunol 107:1081\u20131089","journal-title":"J Immunol"},{"key":"102_CR142","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ygyno.2008.05.036","volume":"110","author":"TF Schwarz","year":"2008","unstructured":"Schwarz TF, Leo O (2008) Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: improving upon nature. Gynecol Oncol 110:S1\u2013S10. https:\/\/doi.org\/10.1016\/j.ygyno.2008.05.036","journal-title":"Gynecol Oncol"},{"key":"102_CR143","doi-asserted-by":"publisher","unstructured":"Seder RA et al (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359\u20131365. https:\/\/doi.org\/10.1126\/science.1241800 [pii]","DOI":"10.1126\/science.1241800"},{"key":"102_CR144","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1001\/jama.2012.6364","volume":"308","author":"SL Sheridan","year":"2012","unstructured":"Sheridan SL, Ware RS, Grimwood K, Lambert SB (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308:454\u2013456. https:\/\/doi.org\/10.1001\/jama.2012.6364","journal-title":"JAMA"},{"key":"102_CR145","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1528-1167.2007.01478.x","volume":"49","author":"S Shorvon","year":"2008","unstructured":"Shorvon S, Berg A (2008) Pertussis vaccination and epilepsy\u2014an erratic history, new research and the mismatch between science and social policy. Epilepsia 49:219\u2013225. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01478.x","journal-title":"Epilepsia"},{"key":"102_CR146","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMe1509442","volume":"373","author":"CP Simmons","year":"2015","unstructured":"Simmons CP (2015) A candidate dengue vaccine walks a tightrope. N Engl J Med 373:1263\u20131264. https:\/\/doi.org\/10.1056\/NEJMe1509442","journal-title":"N Engl J Med"},{"key":"102_CR147","doi-asserted-by":"publisher","unstructured":"Slifka MK, Amanna I (2014) How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32:2948\u20132957. https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.078s0264-410x(14)00459-9 [pii]","DOI":"10.1016\/j.vaccine.2014.03.078s0264-410x(14)00459-9"},{"key":"102_CR148","doi-asserted-by":"publisher","unstructured":"Stanaway JD et al (2016) The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis https:\/\/doi.org\/10.1016\/s1473-3099(16)00026-8","DOI":"10.1016\/s1473-3099(16)00026-8"},{"key":"102_CR149","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1945.02860030016004","volume":"127","author":"J Stokes Jr","year":"1945","unstructured":"Stokes J Jr, Neefe JR (1945) The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127:144\u2013145","journal-title":"JAMA"},{"key":"102_CR150","first-page":"620","volume":"63","author":"S Stokley","year":"2014","unstructured":"Stokley S et al (2014) Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2014United States. MMWR Morb Mortal Wkly Rep 63:620\u2013624","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"102_CR151","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","volume":"16","author":"J Storsaeter","year":"1998","unstructured":"Storsaeter J, Hallander HO, Gustafsson L, Olin P (1998) Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907\u20131916","journal-title":"Vaccine"},{"key":"102_CR152","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/B978-1-4557-0090-5.00028-8","volume-title":"vaccines","author":"PM Strebel","year":"2013","unstructured":"Strebel PM, Papania MJ, Fiebelkorn AP, Halsey NA (2013) Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) vaccines, 6th edn. Saunders\/Elsevier, Philadelphia, pp 352\u2013388","edition":"6"},{"key":"102_CR153","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/INF.0b013e318269433a","volume":"31","author":"JC Tejedor","year":"2012","unstructured":"Tejedor JC et al (2012) Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 31:1074\u20131077. https:\/\/doi.org\/10.1097\/INF.0b013e318269433a","journal-title":"Pediatr Infect Dis J"},{"key":"102_CR154","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"The FUTURE II Study Group","year":"2007","unstructured":"The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915\u20131927","journal-title":"N Engl J Med"},{"key":"102_CR155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"The IMpact RSV Study Group","year":"1998","unstructured":"The IMpact RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531\u2013537","journal-title":"Pediatrics"},{"key":"102_CR156","doi-asserted-by":"publisher","unstructured":"Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N (2015) Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20\u00a0years of observed data, and long-term model-based predictions. Vaccine 33:5723\u20135727. https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.008","DOI":"10.1016\/j.vaccine.2015.07.008"},{"key":"102_CR157","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-1-4557-0090-5.00024-0","volume-title":"Vaccines","author":"T Tiwari","year":"2013","unstructured":"Tiwari T, Wharton M (2013) Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 6th edn. Saunders\/Elsevier, Philadelphia, pp 153\u2013166","edition":"6"},{"key":"102_CR158","doi-asserted-by":"publisher","unstructured":"Tseng HF et al (2016) Declining effectiveness of herpes zoster vaccine in adults aged >\/=60. Years J Infect Dis. https:\/\/doi.org\/10.1093\/infdis\/jiw047 (jiw047 [pii])","DOI":"10.1093\/infdis\/jiw047"},{"key":"102_CR159","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jmv.1890440425","volume":"44","author":"P Van Damme","year":"1994","unstructured":"Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44:446\u2013451","journal-title":"J Med Virol"},{"key":"102_CR160","doi-asserted-by":"publisher","unstructured":"Vaughn DW et al (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity J Infect Dis 181:2\u20139. https:\/\/doi.org\/10.1086\/315215 (JID990867 [pii])","DOI":"10.1086\/315215"},{"key":"102_CR161","doi-asserted-by":"publisher","unstructured":"Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED (2001) The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344:955\u2013960. https:\/\/doi.org\/10.1056\/nejm200103293441302 (MJBA-441302 [pii])","DOI":"10.1056\/nejm200103293441302"},{"key":"102_CR162","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar L et al (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113\u2013123. https:\/\/doi.org\/10.1056\/NEJMoa1411037","journal-title":"N Engl J Med"},{"key":"102_CR163","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0029-1207589","volume":"16","author":"E von Behring","year":"1890","unstructured":"von Behring E, Kitasato S (1890) Ueber das zustandekommen der diphtherie-immunitat und der tetanus-immunitat bei thieren (On the realization of immunity in diphtheria and tetanus in animals). Dtsch Med Wochenschr 16:1113\u20131114","journal-title":"Dtsch Med Wochenschr"},{"key":"102_CR164","doi-asserted-by":"publisher","unstructured":"Walton LR, Orenstein WA, Pickering LK (2015) Lessons learned from making and implementing vaccine recommendations in the U.S. Vaccine 33(Suppl 4):D78\u2013D82. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.036","DOI":"10.1016\/j.vaccine.2015.09.036"},{"key":"102_CR165","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1542\/peds.81.6.886","volume":"81","author":"JI Ward","year":"1988","unstructured":"Ward JI, Broome CV, Harrison LH, Shinefield H, Black S (1988) Haemophilus influenzae type b vaccines: lessons for the future. Pediatrics 81:886\u2013893","journal-title":"Pediatrics"},{"key":"102_CR166","doi-asserted-by":"publisher","unstructured":"Webster DP, Farrar J, Rowland-Jones S (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9:678\u2013687. https:\/\/doi.org\/10.1016\/s1473-3099(09)70254-3 (S1473-3099(09)70254-3 [pii])","DOI":"10.1016\/s1473-3099(09)70254-3"},{"key":"102_CR167","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199208133270702","volume":"327","author":"A Werzberger","year":"1992","unstructured":"Werzberger A et al (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327:453\u2013457. https:\/\/doi.org\/10.1056\/NEJM199208133270702","journal-title":"N Engl J Med"},{"key":"102_CR168","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0264-410X(96)00242-3","volume":"15","author":"G Wiedermann","year":"1997","unstructured":"Wiedermann G, Kundi M, Ambrosch F, Safary A, D\u2019Hondt E, Delem A (1997) Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 15:612\u2013615","journal-title":"Vaccine"},{"key":"102_CR169","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/B978-1-4557-0090-5.00031-8","volume-title":"Vaccines","author":"ED Williamson","year":"2013","unstructured":"Williamson ED, Oyston PCF (2013) Plague vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Saunders\/Elsevier, Philadelphia, pp 493\u2013503","edition":"5"},{"key":"102_CR170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/165.1.119","volume":"165","author":"A Wilson","year":"1992","unstructured":"Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM (1992) Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165:119\u2013126","journal-title":"J Infect Dis"},{"key":"102_CR171","doi-asserted-by":"crossref","unstructured":"Wolters KL, Dehmel H (1942) [Final investigations into tetanus prevention by active immunization] Zeitschrift f\u00fcr hygiene und infektions krankheiten medizinische, mikrobiologie und viralogie 124:326\u2013332","DOI":"10.1007\/BF02178438"},{"key":"102_CR172","first-page":"45","volume":"89","author":"World Health Organization","year":"2014","unstructured":"World Health Organization (2014) Global control and regional elimination of measles, 2000\u20132012. Wkly Epidemiol Rec 89:45\u201352","journal-title":"Wkly Epidemiol Rec"},{"key":"102_CR173","doi-asserted-by":"publisher","unstructured":"Young MK, Nimmo GR, Cripps AW, Jones MA (2014) Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev 4:CD010056 https:\/\/doi.org\/10.1002\/14651858.cd010056.pub2","DOI":"10.1002\/14651858.cd010056.pub2"},{"key":"102_CR174","doi-asserted-by":"publisher","unstructured":"Zhou F et al (2005) Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med 159:1136\u20131144. https:\/\/doi.org\/10.1001\/archpedi.159.12.1136 (159\/12\/1136 [pii])","DOI":"10.1001\/archpedi.159.12.1136"},{"key":"102_CR175","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.1924.02650410022011","volume":"82","author":"A Zingher","year":"1924","unstructured":"Zingher A (1924) Convalescent whole blood plasma and serum in prophylaxis of measles. JAMA 82:1180\u20131187","journal-title":"JAMA"}],"container-title":["Current Topics in Microbiology and Immunology","Vaccination Strategies Against Highly Variable Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2018_102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T23:18:10Z","timestamp":1693783090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/82_2018_102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783030580032","9783030580049"],"references-count":175,"URL":"https:\/\/doi.org\/10.1007\/82_2018_102","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"26 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}